Suppr超能文献

一种用于未来生物人工肝的新型类漏斗形流化床生物反应器的评估

Evaluation of a novel choanoid fluidized bed bioreactor for future bioartificial livers.

作者信息

Yu Cheng-Bo, Pan Xiao-Ping, Yu Liang, Yu Xiao-Peng, Du Wei-Bo, Cao Hong-Cui, Li Jun, Chen Ping, Li Lan-Juan

机构信息

Cheng-Bo Yu, Xiao-Ping Pan, Liang Yu, Xiao-Peng Yu, Wei-Bo Du, Hong-Cui Cao, Jun Li, Ping Chen, Lan-Juan Li, States Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.

出版信息

World J Gastroenterol. 2014 Jun 14;20(22):6869-77. doi: 10.3748/wjg.v20.i22.6869.

Abstract

AIM

To construct and evaluate the functionality of a choanoid-fluidized bed bioreactor (CFBB) based on microencapsulated immortalized human hepatocytes.

METHODS

Encapsulated hepatocytes were placed in the constructed CFBB and circulated through Dulbecco's Modified Eagle's Medium (DMEM) for 12 h, and then through exchanged plasma for 6 h, and compared with encapsulated cells cultivated under static conditions in a spinner flask. Levels of alanine aminotransferase (ALT) and albumin were used to evaluate the CFBB during media circulation, whereas levels of ALT, total bilirubin (TBil), and albumin were used to evaluate it during plasma circulation. Mass transfer and hepatocyte injury were evaluated by comparing the results from the two experimental conditions. In addition, the viability and microstructure of encapsulated cells were observed in the different environments.

RESULTS

The bioartificial liver model based on a CFBB was verified by in vitro experiments. The viability of encapsulated cells accounting for 84.6% ± 3.7% in CFBB plasma perfusion was higher than the 74.8% ± 3.1% in the static culture group (P < 0.05) after 6 h. ALT release from cells was 29 ± 3.5 U/L vs 40.6 ± 3.2 U/L at 12 h (P < 0.01) in the CFBB medium circulation and static medium culture groups, respectively. Albumin secretion from cells was 234.2 ± 27.8 μg/1 × 10(7) cells vs 167.8 ± 29.3 μg/1 × 10(7) cells at 6 h (P < 0.01), 274.4 ± 34.6 μg/1 × 10(7) cells vs 208.4 ± 49.3 μg/1 × 10(7) cells (P < 0.05) at 12 h, in the two medium circulation/culture groups, respectively. Furthermore, ALT and TBil levels were 172.3 ± 24.1 U/L vs 236.3 ± 21.5 U/L (P < 0.05), 240.1 ± 23.9 μmol/L vs 241.9 ± 31.4 μmol/L (P > 0.05) at 6 h in the CFBB plasma perfusion and static plasma culture groups, respectively. There was no significant difference in albumin concentration between the two experimental plasma groups at any time point. The microstructure of the encapsulated hepatocytes remained healthier in the CFBB group compared with the static culture group after 6 h of plasma perfusion.

CONCLUSION

The CFBB can function as a bioartificial liver based on a bioreactor. The efficacy of this novel bioreactor is promising for the study of liver failure.

摘要

目的

构建并评估基于微囊化永生化人肝细胞的类漏斗形流化床生物反应器(CFBB)的功能。

方法

将包囊化的肝细胞置于构建好的CFBB中,使其在杜氏改良 Eagle 培养基(DMEM)中循环12小时,然后在置换血浆中循环6小时,并与在转瓶中静态培养的包囊化细胞进行比较。在培养基循环期间,使用丙氨酸转氨酶(ALT)和白蛋白水平评估CFBB,而在血浆循环期间,使用ALT、总胆红素(TBil)和白蛋白水平评估CFBB。通过比较两种实验条件的结果来评估传质和肝细胞损伤。此外,在不同环境中观察包囊化细胞的活力和微观结构。

结果

基于CFBB的生物人工肝模型通过体外实验得到验证。在CFBB血浆灌注中,6小时后包囊化细胞的活力为84.6%±3.7%,高于静态培养组的74.8%±3.1%(P<0.05)。在CFBB培养基循环组和静态培养基培养组中,细胞在12小时时ALT释放量分别为29±3.5 U/L和40.6±3.2 U/L(P<0.01)。在两种培养基循环/培养组中,细胞在6小时时白蛋白分泌量分别为234.2±27.8 μg/1×10(7)个细胞和167.8±29.3 μg/1×10(7)个细胞(P<0.01),在12小时时分别为274.4±34.6 μg/1×10(7)个细胞和208.4±49.3 μg/1×10(7)个细胞(P<0.05)。此外,在CFBB血浆灌注组和静态血浆培养组中,6小时时ALT和TBil水平分别为172.3±24.1 U/L和236.3±21.5 U/L(P<0.05),240.1±23.9 μmol/L和241.9±31.4 μmol/L(P>0.05)。在任何时间点,两个实验血浆组之间的白蛋白浓度均无显著差异。血浆灌注6小时后,与静态培养组相比,CFBB组中包囊化肝细胞的微观结构保持更健康。

结论

CFBB可作为基于生物反应器的生物人工肝发挥作用。这种新型生物反应器的功效在肝衰竭研究中前景广阔。

相似文献

本文引用的文献

7
Acute liver failure: Summary of a workshop.急性肝衰竭:研讨会总结
Hepatology. 2008 Apr;47(4):1401-15. doi: 10.1002/hep.22177.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验